The right pharma partnership can provide a truly practical and unbiased evaluation in a highly profitable environment. The study will certainly enrich pharma businesses by covering the current situation and the growth of the big pharma partnering deals. The evaluation dissects and finds useful market trends, deals and strategies during the period f
Dublin- Research and Markets has announced the addition of the "Recent FDA-approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. -First FDA Approved Immunotherapy for Metastatic Merkel Cell Carcinoma- Relapsing Multiple Sclerosis Now Has a Novel FDA-approved Drug
Research and Markets has announced the addition of the "Recent FDA- approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Fre
By a News Reporter-Staff News Editor at Women's Health Weekly- AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc., announced detailed results from a Phase 2 b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy compared to placebo. The data demonstrat
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, PhD, will present at the Gene Therapy for Rare Disorders 2017 and the Alliance of Regenerative Medicine 5 th Annual Cell and Gene
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. Raymond James& Associates, Inc. will act as the so
From 2002 to 2010, Dr. Spivey worked with Meda AB after the acquisition of MedPointe Pharmaceuticals, serving as chief scientific officer and head of research and development for both. Earlier in his career, Dr. Spivey worked for Pharmacia Corporation, Schering-Plough Corporation, Parke-Davis/Warner-Lambert, and Boots Pharmaceuticals, Inc..
Right now, the nation is short on safe, effective alternatives to addictive pain drugs called opioids, said Collins, who heads NIH. Collins said the NIH is working with the U.S. Food and Drug Administration and the pharmaceutical industry to find ways to speed up development of non-addictive alternatives to opioids, and to find ways to provide more
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine s 5 th Annual Cell& Gene Therapy In
Alder BioPharmaceuticals , Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the close of U.S. financial markets on Thursday, April 27, 2017. Alder BioPharmaceuticals, Inc., is a clinical-stage...
Aldeyra Therapeutics received an orphan drug designation by the US Food and Drug Administration for ADX-102 in treating the rare disease Sjgren-Larsson Syndrome. The skin disease associated with SLS is physically and emotionally debilitating, leading to considerable social stigma and requiring significant daily care and medical resources, s
Aldeyra Therapeutics, Inc., a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration has granted Aldeyra's novel compound ADX-102 orphan drug designation for the
Allergan plc, a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology annual meeting taking place April 22-28, 2017 in Boston. "Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes Study" Program Speaker: Ann Scher, PhD PL8, In
By a News Reporter-Staff News Editor at Women's Health Weekly- Amgen and UCB announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY?*, an investigational agent for postmenopausal women with osteoporosis. The results were presented in an oral session at ENDO 2017, th
WALTHAM, Mass.& VIENNA Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the company will be reporting data in five poster presentations at the 27th European Congress of Clinical Microbiology and...
Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that its collaborating investigators at the Queensland Institute of Medical Research and The University of Queensland are reporting...
Atossa Genetics, Inc., a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its Phase 1 study of endoxifen, which is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high risk patients. The study is being conducted on b
Aurinia Pharmaceuticals Inc. a clinical stage biopharmaceutical company focused on the global immunology market, today announced additional 48- week results from its global Phase IIb AURA-LV study in lupus nephritis during the National Kidney Foundation 2017 Spring Clinical Meetings in Orlando, FL. In addition to the trial meeting its complete and.
Avantor Performance Materials, LLC, announced today the acquisition of Puritan Products, Inc., a supplier of cGMP buffers and solutions for Biopharma customers, and high-purity chemistries for Research and Electronic Materials customers. Avantor is a global supplier of ultra-high-purity materials for the life sciences and advanced technology...
-Second trial investigating PROSTVAC in combination with checkpoint inhibitors from Bristol-Myers Squibb. COPENHAGEN, Denmark, April 19, 2017- Bavarian Nordic A/S today announced the initiation of a Phase 2 clinical trial of its prostate cancer immunotherapy candidate, PROSTVAC, in combination treatment with YERVOY and/or OPDIVO, both of which are
CAMBRIDGE, England& CAMBRIDGE, Mass. Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic ma
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit in its Phase 2 b trial was on March 24, 2017 and the last investigational site close-out visit was April 7, 2017. BioPharmX Corporation is a Silicon Valley- based specialty pharmaceutical company that seeks to
Under evaluation this morning are: Biostage Inc., Keryx Biopharmaceuticals Inc., Kite Pharma Inc., and ZIOPHARM Oncology Inc.. Shares in Holliston, Massachusetts headquartered Biostage Inc. jumped 3.42%, ending Wednesday's trading session at $0.31. On April 18 th, 2017, Biostage announced that it has appointed Stephen F. Badylak DVM, PhD, MD to its
LONDON, UK/ ACCESSWIRE/ April 20, 2017/ Active Wall St. blog coverage looks at the headline from CytRx Corp. as the Company announced on April 19, 2017, that the US Food and Drug Administration has agreed to a rolling submission for a New Drug Application submission for the Company's aldoxorubicin drug for the treatment of soft tissue sarcomas.